Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Consensus Recommendation of "Hold" by Brokerages

Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) has been assigned a consensus recommendation of "Hold" from the nine brokerages that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, six have given a hold recommendation and two have issued a buy recommendation on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $8.63.

Separately, HC Wainwright reissued a "neutral" rating and issued a $4.00 price objective on shares of Fulcrum Therapeutics in a research note on Wednesday, February 26th.

Fulcrum Therapeutics Price Performance

Shares of Fulcrum Therapeutics stock traded down $0.08 during trading on Tuesday, reaching $3.01. 143,341 shares of the stock traded hands, compared to its average volume of 951,131. Fulcrum Therapeutics has a 52-week low of $2.78 and a 52-week high of $10.13. The business has a fifty day simple moving average of $3.53 and a two-hundred day simple moving average of $3.76. The company has a market capitalization of $162.48 million, a price-to-earnings ratio of -9.71 and a beta of 2.20.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.03). On average, research analysts predict that Fulcrum Therapeutics will post -0.16 earnings per share for the current fiscal year.

Remove Ads

Institutional Investors Weigh In On Fulcrum Therapeutics

Several institutional investors have recently made changes to their positions in FULC. Mackenzie Financial Corp grew its stake in shares of Fulcrum Therapeutics by 412.5% during the fourth quarter. Mackenzie Financial Corp now owns 118,025 shares of the company's stock valued at $555,000 after buying an additional 94,997 shares during the last quarter. Woodline Partners LP grew its holdings in shares of Fulcrum Therapeutics by 110.3% in the fourth quarter. Woodline Partners LP now owns 1,410,520 shares of the company's stock worth $6,629,000 after purchasing an additional 739,713 shares during the last quarter. Suvretta Capital Management LLC increased its stake in Fulcrum Therapeutics by 182.3% in the 4th quarter. Suvretta Capital Management LLC now owns 3,338,466 shares of the company's stock worth $15,691,000 after buying an additional 2,155,675 shares during the period. Shay Capital LLC lifted its holdings in Fulcrum Therapeutics by 4.2% during the 4th quarter. Shay Capital LLC now owns 301,464 shares of the company's stock valued at $1,417,000 after buying an additional 12,227 shares in the last quarter. Finally, Millennium Management LLC boosted its position in Fulcrum Therapeutics by 224.0% in the 4th quarter. Millennium Management LLC now owns 76,123 shares of the company's stock valued at $358,000 after buying an additional 52,628 shares during the period. Institutional investors own 89.83% of the company's stock.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.